Last reviewed · How we verify
NCT05916547
Safety and Efficacy of P-ESWL and ERCP
trial testing pancreatic extracorporeal shock wave lithotripsy in Pancreatic Duct Stone in 2,071 participants. Completed in 1 May 2024.
26 April 2024
Quick facts
| Lead sponsor | Changhai Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 2,071 |
| Start date | 1 June 2023 |
| Primary completion | 26 April 2024 |
| Estimated completion | 1 May 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- pancreatic extracorporeal shock wave lithotripsy
Conditions studied
- Pancreatic Duct Stone — all drugs for Pancreatic Duct Stone →
Sponsor
Changhai Hospital
Who can join
Eligibility, any sex, with Pancreatic Duct Stone. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To determine the types, incidence and risk factors of adverse events after pancreatic extracorporeal shock wave lithotripsy (P-ESWL) and endoscopic retrograde cholangiopancreatography (ERCP), define the grading criteria of adverse events after P-ESWL and ERCP, and analyze the efficacy of P-ESWL and ERCP, which will provide evidence-based medical evidence to guide physicians' clinical practice.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Long-term clinical outcomes of extracorporeal shockwave lithotripsy and endoscopic retrograde cholangiopancreatography for pancreatic duct stone treatment in patients with chronic pancreatitis.
Liu Y, Yin XY, Cui JH, Wang T, et al · · 2024 · cited 7× · PMID 39169663 · DOI 10.1111/apt.18224 -
Safety evaluation of extracorporeal shockwave lithotripsy for pancreatic stones: Experience based on a large chronic pancreatitis cohort.
Liu Y, Yi JH, Wang PY, Fu P, et al · · 2025 · cited 2× · PMID 39261265 · DOI 10.1016/j.dld.2024.08.043
Verify or expand the search:
- PubMed search for NCT05916547
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Changhai Hospital trials
Trials by the same sponsor.
- NCT07490002 — Neoadjuvant Therapy With Iparomlimab and Tuvonralimab, Lenvatinib and Chemotherapy in Resectable ESCC · Phase 2 · not yet recruiting
- NCT07464392 — FMT for the Prevention of Infectious Complications in Patients With Moderately Severe and Severe Acute Pancreatitis · NA · recruiting
- NCT07507071 — Comparison of the Sensitivity of pCLE and Pathological Biopsy for Gastric Mucosal Lesions · not yet recruiting
- NCT07481591 — Capsule Endoscopy in GI Bleeding: A Retrospective Study · not yet recruiting
- NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05916547 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Changhai Hospital
- Last refreshed: 11 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05916547.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing